Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00418496
Status:
COMPLETED
Last Update Posted:
2017-02-20
First Post:
2007-01-02
Brief Title:
Interleukin-2 With Sorafenib BAY 43-9006 for Unresectable or Metastatic Clear Cell Renal Carcinoma RCC and Metastatic Melanoma
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization:
Ohio State University Comprehensive Cancer Center
Organization Data
Organization:
Ohio State University Comprehensive Cancer Center
Class:
OTHER
Study ID:
OSU-06006
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
Paul Monk
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Ohio State University Comprehensive Cancer Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
| Bayer | INDUSTRY |